Amgen Inc (AMGN) stock
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$457.93−4.39 (-0.95%)
Close on Nov 17, 2026Market cap $247.57BP/E 26.5Yield 2.11%
Amgen price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Amgen's price to book ratio was 21.7× on Nov 11, 2026, against 19.3× a year earlier. Over the last 5 years it ranged from 15.5× to 149.7×, with a median of 22.6×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 21.7× | +3.3 |
| 2025 | Dec 31, 2025 | 18.3× | −0.3 |
| 2024 | Dec 31, 2024 | 18.6× | −1.5 |
| 2023 | Dec 29, 2023 | 20.1× | −18.2 |
| 2022 | Dec 30, 2022 | 38.4× | +22.9 |
| 2021 | Dec 31, 2021 | 15.5× | +3.2 |
| 2020 | Dec 31, 2020 | 12.2× | −1.2 |
| 2019 | Dec 31, 2019 | 13.4× | +4.6 |
| 2018 | Dec 31, 2018 | 8.8× | +4.9 |
| 2017 | Dec 29, 2017 | 3.9× | +0.4 |
| 2016 | Dec 30, 2016 | 3.5× | −0.8 |
| 2015 | Dec 31, 2015 | 4.4× | −0.4 |
| 2014 | Dec 31, 2014 | 4.8× | +0.8 |
| 2013 | Dec 31, 2013 | 4.0× | +0.6 |
| 2012 | Dec 31, 2012 | 3.3× | +0.9 |
| 2011 | Dec 30, 2011 | 2.4× | +0.2 |
| 2010 | Dec 31, 2010 | 2.2× | −0.3 |
| 2009 | Dec 31, 2009 | 2.5× | – |
See a number that looks wrong?